Industry association Pharma Deutschland has expressed disappointment at the German switch committee’s (SVA’s) recent rejection of the Rx-to-OTC switch of sildenafil.
German Industry ‘Disappointed’ At Sildenafil’s Third Rx-To-OTC Switch Rejection
“The SVA has missed an opportunity to make an important contribution to patient safety and to strengthening personal responsibility,” commented Pharma Deutschland deputy general manager Elmar Kroth.
